An effective drug for treating Parkinson’s disease is now available in India as the Vikram Hospital of Bengaluru has joined hands with UK-based speciality pharmaceutical company Britannia Pharmaceuticals to introduce “Apomorphine” for the first time in India.
Parkinson’s disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. And in India, currently patients suffering from Parkinson’s have only two options: oral treatment for early stages and Deep Brain Stimulation (DBS) surgery for later stages – there is no treatment for middle stages. Also, since the DBS surgery is very expensive, it becomes unaffordable for a number of people and surgery is not a choice for all age groups either – leaving out a huge number of PD patients vulnerable to serious and fatal conditions due to unavailability of proper treatment in the country.
Ending the distress, a private hospital in Bengaluru named the Vikram Hospital has associated with UK-based specialty pharmaceutical company Britannia Pharmaceuticals to launch India’s very first Apomorphine treatment. Available in two options – injections and infusion pumps, this medicine has been a popular cure for Parkinson’s since 15 years but was not available in India due to lack of regulatory approvals. The medicine is an effective, easy and cheaper option to cure patients who are not the right candidates for DBS, or those who do not need the surgery or are too young or old to undergo any surgeries.
The availability of Apomorphine in India will help medics in treating patients with middle stage PD as the drug stimulates the production of dopamine by nerve cells in the brain. The dopamine triggers quick and effective relief to patients and also promise better life quality – if not cure completely. This is especially good for India as the World Health Organization (WHO) has estimated that the number of PD patients will increase by 330% in India and Apomorphine is the way to battle it.